DUBLIN, May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its ...

Alkermes (ALKS) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.01 per share a year ago. These figures are ...

Alkermes (ALKS) reported $350.37 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 21.8%. EPS of $0.44 for the same period compares to $0.01 a year ago.The ...

"The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company. During the quarter, we continued to advance our strategic priorities acros ...

Below are the earnings highlights for Alkermes plc (ALKS): Earnings: $36.83 million in Q1 vs. -$41.85 million in the same period ...

DUBLIN — DUBLIN — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based company said it had ...

Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and ...

The Wilmington-Clinton County Chamber of Commerce’s 2024 Annual Meeting, a hallmark event for local businesses and community ...

Six fast-growing startups have been selected to receive a $100,000 investment each and will participate in the 12-week ...

Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report) and Ocular ...

Q1 2024 Earnings Call Transcript April 30, 2024 Harmony Biosciences Holdings, Inc. beats earnings expectations. Reported EPS ...